Publication Year: 2014
-
Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarkerstratified, randomised phase 3 trial
-
Serum–based test to identify patients with early relapse treated with adjuvant hormonal therapy
-
Serum mass-spectrometry test in first line advanced NSCLC patients treated with standard chemotherapy regimens
-
Efficacy analysis of gefitinib +/- ficlatuzumab in serum proteomic-based subgroups of patients with previously untreated lung adenocarcinoma
-
Proteomic Signature Predicts Response To A Therapeutic Vaccine In Pancreas Cancer, Analysis Of Gi-4000-02